SCHEMBL497316

SCHEMBL497316

CSOc1c(C(C)=O)c(=O)[nH]c2ccccc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.58
TDP1 Q9NUW8 1/20 0.49
ALDH1A1 P00352 6/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
HSD17B10 Q99714 2/20 0.48
HPGD P15428 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.46
NLRP3 Q96P20 1/20 0.46
MAPT P10636 3/20 0.44
GAA P10253 1/20 0.44
POLB P06746 1/20 0.43
DAO P14920 1/20 0.42
DDO Q99489 1/20 0.42
IDE P14735 1/20 0.41
MPI P34949 1/20 0.41
CACNA1B Q00975 1/20 0.41
APBA1 Q02410 1/20 0.41
NR4A2 P43354 1/20 0.41
TNKS O95271 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7804026 0.81 RXFP1 (0.45) KDM4EDAONR4A2LMNAPARP1
SCHEMBL7804167 0.80 ALDH1A1 (0.46) KDM4ETDP1ALDH1A1MEN1KMT2A
SCHEMBL7809500 0.80 KDM4E (0.45) KDM4EALDH1A1MEN1KMT2AHSD17B10
SCHEMBL29612326 0.79 KDM4E (0.65) KDM4ETDP1ALDH1A1MEN1KMT2A
SCHEMBL7816823 0.79 KDM4E (0.65) KDM4ETDP1ALDH1A1MEN1KMT2A
SCHEMBL7813789 0.79 FEN1 (0.39) KDM4EALDH1A1KMT2ASMN1; SMN2DAO
SCHEMBL7809535 0.78 FEN1 (0.42) KDM4ETDP1ALDH1A1MEN1KMT2A
SCHEMBL7809669 0.78 DAO (0.40) KDM4EALDH1A1MEN1KMT2AHSD17B10
SCHEMBL7817120 0.77 CAPN1 (0.44) KDM4EALDH1A1MEN1KMT2AHSD17B10
SCHEMBL7803963 0.77 DAO (0.39) KDM4EALDH1A1MEN1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2124948-B1 COMPOSITIONS FOR TREATING HYPERPROLIFERATIVE VASCULAR DISORDERS AND CANCERS NC BIT INC (KR) 2017-07-26 EP disclosed
US-8106071-B2 Compositions for treating hyperproliferative vascular disorders and cancers BIOBUD CO., LTD. (KR) 2012-01-31 US disclosed
US-20100120849-A1 Compositions for Treating Hyperproliferative Vascular Disorders and Cancers BIOBUD CO., LTD (KR) 2010-05-13 US disclosed
EP-2124948-A1 COMPOSITIONS FOR TREATING HYPERPROLIFERATIVE VASCULAR DISORDERS AND CANCERS Biobud Co., Ltd. (KR) 2009-12-02 EP disclosed
WO-2008102932-A1 COMPOSITIONS FOR TREATING HYPERPROLIFERATIVE VASCULAR DISORDERS AND CANCERS BIOBUD CO., LTD. (KR) 2008-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120849-A1 Compositions for Treating Hyperproliferative Vascular Disorders and Cancers MKI67, MYLK, PCNA KDM4E 2304/4885TDP1 766/4885ALDH1A1 2874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.